TLR7 gain-of-function genetic variation causes human lupus

Grant J. Brown(Australian National University), Pablo F. Cañete(Australian National University), Hao Wang(Australian National University), Arti Medhavy(Australian National University), Josiah Bones(Australian National University), Jonathan A. Roco(Australian National University), Yuke He(Renji Hospital), Yuting Qin(Renji Hospital), Jean Cappello(Australian National University), Julia I. Ellyard(Australian National University), Katharine Bassett(Australian National University), Qian Shen(Australian National University), Gaétan Burgio(Australian National University), Yaoyuan Zhang(Australian National University), Cynthia Turnbull(Australian National University), Xiangpeng Meng(Australian National University), Phil Wu(Australian National University), Eun Cho(Australian National University), Lisa A. Miosge(Australian National University), T. Daniel Andrews(Australian National University), Matthew A. Field(Australian National University), Denis Tvorogov(South Australia Pathology), Angel F. López(South Australia Pathology), Jeffrey J. Babon(Walter and Eliza Hall Institute of Medical Research), Cristina Aparicio López(Hospital Infantil Universitario Niño Jesús), África González‐Murillo(Hospital Infantil Universitario Niño Jesús), Daniel Clemente(Hospital Infantil Universitario Niño Jesús), Virginia Pascual(Cornell University), Tess Levy(Icahn School of Medicine at Mount Sinai), Eric J. Mallack(NewYork–Presbyterian Hospital), Daniel G. Calame(Baylor College of Medicine), Timothy Lotze(Baylor College of Medicine), James R. Lupski(Baylor College of Medicine), Huihua Ding(Shanghai Jiao Tong University), Tomalika R. Ullah(Hudson Institute of Medical Research), Giles Walters(Canberra Hospital), Mark E. Koina(Canberra Hospital), Matthew Cook(Australian National University), Nan Shen(Cincinnati Children's Hospital Medical Center), Carmen de Lucas Collantes(Hospital Infantil Universitario Niño Jesús), Ben Corry(Australian National University), Michael P. Gantier(Shanghai Jiao Tong University), Vicki Athanasopoulos(Australian National University), Carola G. Vinuesa(South Australia Pathology)
Nature
April 27, 2022
Cited by 550Open Access
Full Text

Abstract

Abstract Although circumstantial evidence supports enhanced Toll-like receptor 7 (TLR7) signalling as a mechanism of human systemic autoimmune disease 1–7 , evidence of lupus-causing TLR7 gene variants is lacking. Here we describe human systemic lupus erythematosus caused by a TLR7 gain-of-function variant. TLR7 is a sensor of viral RNA 8 , 9 and binds to guanosine 10 – 12 . We identified a de novo, previously undescribed missense TLR7 Y264H variant in a child with severe lupus and additional variants in other patients with lupus. The TLR7 Y264H variant selectively increased sensing of guanosine and 2',3'-cGMP 10–12 , and was sufficient to cause lupus when introduced into mice. We show that enhanced TLR7 signalling drives aberrant survival of B cell receptor (BCR)-activated B cells, and in a cell-intrinsic manner, accumulation of CD11c + age-associated B cells and germinal centre B cells. Follicular and extrafollicular helper T cells were also increased but these phenotypes were cell-extrinsic. Deficiency of MyD88 (an adaptor protein downstream of TLR7) rescued autoimmunity, aberrant B cell survival, and all cellular and serological phenotypes. Despite prominent spontaneous germinal-centre formation in Tlr7 Y264H mice, autoimmunity was not ameliorated by germinal-centre deficiency, suggesting an extrafollicular origin of pathogenic B cells. We establish the importance of TLR7 and guanosine-containing self-ligands for human lupus pathogenesis, which paves the way for therapeutic TLR7 or MyD88 inhibition.


Related Papers

No related papers found

Powered by citation graph analysis